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Abstract The discovery of the Warburg effect in the
early twentieth century followed by the development of
the fluorinated glucose analogue 18F-fluorodeoxyglucose
(18F-FDG) and the invention of positron emission tomo-
graphs laid the foundation of clinical PET/CT. This review
discusses the challenges and obstacles in clinical adoption
of this technique. We then discuss advances in instru-
mentation, including the critically important introduction
of PET/CT and current PET/CT protocols. Moreover, we
provide evidence for the clinical utility of PET/CT for
patient management and its potential impact on patient
outcome, and address its cost and cost-effectiveness.
Although this review largely focuses on 18F-FDG imaging,
we also discuss a variety of additional molecular imaging
approaches that can be used for cancer phenotyping with
PET. Throughout this review we emphasize the critical
contributions of CT to the strength of PET/CT.
Keywords PET/CT  Oncology  Initial treatment
strategies  Subsequent treatment strategies  Molecular
imaging
Introduction
The foundation of clinical PET/CT was laid by several
pivotal events (Fig. 1) that date back as far as the early
twentieth century when Otto Warburg [1, 2] discovered
that cancer cells switch from oxidative to glucose metab-
olism even in the presence of oxygen (aerobic glycolysis;
Warburg effect). More than three decades later, Luis
Sokoloff [3, 4] demonstrated that 14C-deoxyglucose auto-
radiography could be used to map and quantify functional
neuroanatomical pathways ex vivo. The translation of this
approach became feasible when the fluorinated glucose
analogue 18F-fluorodeoxyglucose (18F-FDG) was devel-
oped [5] and Phelps and Hoffmann [6, 7] invented and built
the first positron emission tomograph, which made possible
the visualization of glycolytic activity in vivo.
Subsequently, 18F-FDG and 13N-ammonia were used to
investigate regional cerebral blood flow and glucose
metabolism in patients with epilepsy [8], stroke [9], cancer
[10, 11], and dementia [12]. 18F-FDG PET for tumor
detection was first reported in animal models in 1980 [13],
and subsequently in human lung neoplasms in 1987 [14].
PET oncology research accelerated with the develop-
ment of whole body PET image acquisition protocols [15].
However, clinical adoption was slow, which was explained
by (1) the limited number of cyclotrons required for pro-
duction of PET probes, (2) the practice patterns of oncol-
ogists that relied largely on anatomical information for
determining initial and subsequent treatment strategies in
cancer, and (3) limited or complete lack of reimbursement
for clinical PET studies.
The hybrid PET/CT technology introduced by Town-
send, Nutt, and Beyer [16] in 1998, the emergence of
commercial distribution networks for 18F-FDG, together
with broadened coverage by the Centers of Medicare and
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Medicaid Services based on an extensive literature review
[17] changed the landscape of cancer imaging. More than
2,500 PET/CT scanners are currently operational in the
USA, and the number of clinical PET studies exceeds two
million per year.
Given the critically important role of PET/CT in
oncology, an appraisal of the current status and perspec-
tives of PET/CT is warranted. Here we discuss advances in
PET/CT instrumentation and describe the information that
can be derived from the combination of anatomical, func-
tional, and molecular imaging. We then discuss current
PET/CT protocols as implemented at our institution and
report on initial attempts to standardize image acquisition,
reconstruction, and interpretation. We also provide evi-
dence for the clinical utility of PET/CT for patient man-
agement and its potential impact on patient outcome and
address its cost and cost-effectiveness. Although this
review largely focuses on 18F-FDG imaging, we will also
discuss a variety of additional molecular imaging approa-
ches that can be used for cancer phenotyping with PET.
Throughout this review, we emphasize the critical contri-
butions of CT to the strength of PET/CT.
Advances in Instrumentation
Beyer et al. reported the design of the first PET/CT scanner
[16]. Its conceptual advantages included near ideal align-
ment between PET and CT images and CT-based correc-
tions for photon attenuation [18]. The prototype consisted
of a single-detector spiral CT scanner and a half-ring PET
scanner. Initial studies conducted at the University of
Pittsburgh demonstrated a diagnostic advantage of the
hybrid system over PET and CT alone by more accurate
lesion localization and improved diagnostic confidence
[19].
Since 1998, both the PET component and the CT com-
ponent of PET/CT systems have improved dramatically.
For PET, fast scintillators with high stopping power such as
lutetium orthosilicate and gadolinium orthosilicate have
become available and have made time-of-flight PET a
clinical reality [20, 21]. Routine use of time-of-flight PET
led to a significant improvement in lesion detection, espe-
cially when images display significant background noise
[22]. Smaller detectors resulted in improved spatial reso-
lution. Moreover, high count rate statistics permit image
acquisition times as short as 1 min per bed position in some
patients [23]. Iterative image reconstruction methods such
as ordered subset expectation maximization resulted in
further improvements in image quality [24].
At the same time, significant improvements in CT
instrumentation occurred. CT devices equipped with 64
detectors are now routinely incorporated in PET/CT. Whole-
body anatomical images of high diagnostic quality can thus
be acquired in a few seconds and are used for photon atten-
uation correction while at the same time providing diagnostic
information.
Embedding Tumor Biology in Anatomy
Cancer detection, staging, restaging, and therapy monitor-
ing has traditionally been the domain of anatomical
imaging. With deeper insights into tumor biology, the
limitations of the anatomical approach have become evi-
dent [25••]. For instance, soft tissue masses are composed
of viable tumor, necrosis, fibrosis, and inflammation, dis-
tinctions that cannot be made on the basis of anatomical
assessments. Neither the dignity of the viable tumor com-
ponent nor its grade or biological behavior can be reliably
predicted from the appearance, shape, or size of anatomical
masses. Changes in tumor size do not reliably predict
tumor responses to therapy. Histologically identical tumors
may have very different genotypes and phenotypes [26], an
important observation with significant therapeutic impli-
cations and consequences.
Fig. 1 Pivotal events in the history of PET. CMS Centers of Medicare and Medicaid Services, 14C-DG 14C-deoxyglucose, 18F-FDG
18F-fluorodeoxyglucose, NOPR National Oncologic PET Registry
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Yet anatomy provides a highly useful framework within
which tumor biology can be studied with PET. Thus, PET
and CT contribute equally to the value and strength of
PET/CT. For instance, surgical interventions, radiation
therapy, or biopsy planning rely on presurgical anatomical
imaging studies. However, by more precise cancer staging,
PET plays a pivotal role in stratifying patients into those
who benefit versus those who do not benefit from surgery
[27]. Moreover, target definition and dose painting can be
improved by PET prior to radiation therapy [28] and PET
can guide interventional radiologists to the most appro-
priate biopsy site [29].
Assessing tumor responses to therapy in cancer patients
is the strength and domain of 18F-FDG PET [30]. However,
combining metabolic with anatomical information by
measuring total lesion glycolysis [31] or total metabolic
tumor volume [32, 33] might further improve treatment
response predictions.
Reading Molecular Cancer Signatures with PET
Nearly 100 years ago, Otto Warburg observed that prolif-
erating tumor cells more readily metabolize glucose to
lactate despite nonlimiting oxygen conditions. This energy-
inefficient process, termed aerobic glycolysis, provides
tumors with the ability to rapidly generate the macromol-
ecules required for cell proliferation and growth. The high
glucose utilization of cancer cells is enabled through a
metabolic rewiring driven by altered signal transduction
pathways. For example, mutations in the RAS–MAPK–
ERK and PI3K–Akt–mTOR pathways and SRC can induce
higher glucose uptake through modulating glucose trans-
porter expression and translocation [34–36]. In addition to
its roles in stimulating glucose transport, Akt can also
promote hexokinase 1 and phosphofructokinase activity;
these are two important enzymes in the production of
glycolytic intermediates [37–39]. Furthermore, overex-
pression of the transcription factors MYC and HIFa, whose
expression can be regulated by PI3K–Akt–mTOR, can
influence the expression of several genes associated with
glycolysis [37]. These include glucose transporters and
specific enzymes that promote the aerobic glycolysis phe-
notype, such as PKM2 and PDK1 [40–42]. Thus, 18F-FDG
PET images depict the complex interplay among gene
expression [43], translation, and various signal transduction
pathways (reviewed in [44]). The information extracted
from these images can provide insights into tumor prolif-
erative activity, aggressiveness [45, 46], and prognosis
[47]. Moreover, 18F-FDG PET might be a useful readout of
therapeutic interventions targeting one or several of these
signal transduction pathways. However, a limitation is the
limited specificity of 18F-FDG PET owing to physiologic
glucose consumption that can occur in benign tissue (e.g.,
brown fat, colonic and pelvic activity, infection and
inflammations, and rebound thymic hyperplasia).
Other metabolic pathways provide nutrients and meta-
bolic building blocks for cancer cells. This is important
because alternative metabolic pathways can be exploited
for PET of tumors that exhibit low glycolytic activity [48].
For instance, glutamine transport and metabolism, con-
trolled by MYC, is upregulated in many cancers [49]. This
may represent an alternative to glucose metabolism, or
more likely, a synergistic strategy of cancer cells to gen-
erate the energy required for growth and survival.
Increased amino acid transport and metabolism may
provide important prognostic information. L-type amino
acid transporter 1 (LAT1) expression was correlated with
long-term outcome in lung cancer patients [50] and pan-
creatic cancer patients [51]. Consistently, the degree of
11C-methionine uptake was correlated with LAT1 expres-
sion in glioblastoma [52], which in turn may provide
prognostic information. 18F-DOPA has been used to diag-
nose and grade primary brain tumors [53, 54], and brain
tumor recurrence [55] can be readily detected with this
PET probe. Increased tumor 18F-DOPA concentration in
patients with suspected brain tumor recurrence provides
important prognostic information [56].
As mentioned above, the PI3K–Akt–mTOR pathway is a
key regulator of tumor cell metabolism. In addition to its
role in glycolysis, its activation can also promote lipid
biosynthesis for cell membrane incorporation [57].
11C-choline and 11C-acetate, imaging probes that target cho-
line kinase and fatty acid synthase, respectively, have been
used to image increased lipid incorporation into membrane
lipid pools in primary and metastatic prostate cancer [58–63]
and hepatocellular carcinoma [64]. 11C-choline prostate can-
cer imaging has already been introduced into clinical practice
in several centers in Europe [65]. Identifying the exact
localization of primary, recurrent, or regionally metastatic
prostate cancers and thus making possible targeted interven-
tions requires accurate anatomical assessments, which
underscores the importance of hybrid imaging modalities.
Tumor cell proliferation can be imaged with 18F-fluo-
rothymidine (18F-FLT), a thymidine analogue that enters
tumor cells via nucleoside transporters and is phosphory-
lated by thymidine kinase 1 [66]. It can thus serve as a
marker of tumor cell proliferation. Significant correlations
between 18F-FLT uptake and the expression of the prolif-
eration marker Ki-67 have been demonstrated in lung
cancer [67], colorectal cancer [68], hepatocellular carci-
noma [69], and other types of cancer (reviewed in [70]).
However, changes in tumor 18F-FLT uptake in response to
treatment were unrelated to histopathological response and
Ki-67 expression in soft tissue sarcoma [71, 72]. Thus,
various chemotherapies might affect tumor 18F-FLT uptake
Curr Radiol Rep (2013) 1:177–190 179
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and uncouple it from biological indices of proliferation
through a variety of mechanisms [71]. The role of 18F-FLT
imaging in managing cancer patients thus awaits further
clarification.
Links between hormone receptor expression and
18F-FDG uptake in breast cancer have been reported. For
instance, triple-negative breast cancers that are known to
carry a poor prognosis exhibit significantly higher 18F-FDG
uptake than estrogen and/or progesterone receptor positive
tumors [73]. Thus, metabolic phenotyping of cancers with
PET might provide important prognostic information.
Estrogen receptor expression can be imaged directly
with PET, which permits response predictions to hormonal
therapy in breast cancer [74]. Similarly, androgen receptors
expressed in primary or metastatic prostate cancers have
been imaged with 18F-fluorodihydrotestosterone, which
binds to their ligand-binding domain [75]. More recently, a
fully humanized, radiolabeled antibody against prostate-
specific membrane antigen was developed to image intra-
cellular androgen receptor signaling [76, 77].
These imaging probes might be useful for improved non-
invasive phenotyping of prostate cancers, which in turn should
make possible more individualized therapeutic approaches.
Other receptor-based approaches include the imaging of
somatostatin and bombesin receptors in a variety of neu-
roendocrine tumors and prostate cancer, respectively [78].
Assessing the expression of these receptors in sometimes
very small tumor lesions mandates the use of anatomical
imaging for exact localization of tracer accumulation.
Highly specific imaging approaches use antibodies,
diabodies, or minibodies that target cell surface structures.
These molecules can be labeled with diagnostic/therapeutic
radioisotope pairs, such as 64Cu/67Cu, 86Y/90Y, and
124I/131I (reviewed in [79]). Thus, theranostic approaches
have become feasible and organ tracer distribution in well-
defined anatomical volumes (by CT) can provide critically
important and accurate dosimetry data for radioimmuno-
therapy or radiopeptide therapy. The anatomical frame-
work provided by CT is also of pivotal importance for cell
trafficking by various PET reporter gene imaging approa-
ches, for instance, when therapeutic cells are dispersed
throughout the whole body [80].
In summary, a large and diverse portfolio of molecular
PET probes has emerged that can be used for cancer phe-
notyping by addressing most of the hallmarks of cancer
[81••].
Structural and Functional Information Derived
from CT
Tumor size cannot be measured accurately with PET. Such
measurements derived from CT (albeit with limitations) are
important for T staging and for determining cancer inva-
sion into adjacent tissues [82]. Despite considerable limi-
tations, changes in tumor size are still most frequently used
to determine tumor responses to therapy [83], and ana-
tomical information is indispensable for the planning of
biopsy, surgery, and radiation therapy.
Yet, CT images might also identify specific tumor
phenotypes. For instance, tumor perfusion can be estimated
by employing dynamic CT at high temporal resolution.
Such measurements require the intravenous administration
of contrast agents, the measurement of tissue density
before, during, and after contrast agent administration, and
the definition of regions of interest, from which the arterial
density input function can be derived. With use of kinetic
models, the density–time data of the arterial input function
and those of the tumor can then be used to estimate tumor
perfusion [84]. Such measurements have revealed perfu-
sion differences between normal tissues and cancers, and
tumor perfusion rates were significantly correlated with
microvascular density and vascular endothelial growth
factor expression in lung cancer [85, 86] and pancreatic
cancer [87] (reviewed in [84]). These measurements
expose patients to considerable levels of ionizing radiation,
ranging from 12.3 to 36.7 mSv [88]. However, such mea-
surements are relevant because they (1) may inform about
tumor vascularity and angiogenesis and thus provide
important prognostic information, (2) provide predictive
information about responses to antiangiogenic drugs, and
(3) may allow predictions about efficient drug delivery to
tumors.
Measurements of tumor heterogeneity or tumor texture
may also enhance the information that can be derived from
CT images. Differences in texture might reflect variable
tissue vascularization. Tumor texture was correlated with
the degree of tumor hypoxia and angiogenesis [89].
Methods of texture analysis are also under development for
18F-FDG PET [90].
In summary, PET/CT is by far the most mature and
comprehensive technology for structural, functional, and
molecular phenotyping of cancer at the whole-body level.
Its applications are near limitless in oncology and include
diagnosing, staging, therapy monitoring, and treatment
stratification.
PET/CT Protocols
PET/CT protocols differ among institutions and countries
[91, 92]. PET/CT studies can be performed with or without
single-phase or multiphase intravenous and/or oral
administration of contrast agent so that fully diagnostic
anatomical and molecular whole-body surveys can be
obtained. Contrast CT studies for PET/CT appear to result
180 Curr Radiol Rep (2013) 1:177–190
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in incremental improvements in diagnostic accuracy in
some cancers. At the University of California, Los Ange-
les, we inject 7.4 mBq of 18F-FDG per kilogram intrave-
nously after a 4–6 h fast (Fig. 2). Contrast agent is given
orally at the time of the tracer injection. Following a 1-h
uptake period, patients are positioned on the scanner table.
The scan commences with a breath-hold chest CT scan to
identify small lung nodules that may be missed during
shallow breathing [93].
Following the breath-hold chest CT scan, we intrave-
nously administer contrast agent using protocols that best
address the clinical problem. The feasibility of multiphase
contrast protocols for PET/CT has recently been reported
[94, 95].
The whole-body contrast CT and PET images are
acquired during shallow breathing, which results in
acceptable alignment between the PET and CT images
[96]. The whole-body contrast CT image is used for
diagnostic purposes and for attenuation correction [18]. We
use oral and intravenous administration of contrast agents
in all patients in whom a stand-alone CT study would
employ such protocols.
We use weight-based protocols for PET studies with
shorter acquisition times in light patients and longer
acquisition times in heavy patients [23]. The total scan
times for whole-body PET/CT protocols with intravenous
administration of contrast agent average less than 30 min
per patient and can be as short as 15 min. Thus, a true ‘‘one
stop shop’’ diagnostic imaging approach has become fea-
sible [97].
Clinical Utility of PET/CT
In 2007 we reported that 18F-FDG PET/CT was superior to
conventional imaging and PET or CT alone for staging and
restaging of most cancers [98]. Subsequent studies con-
firmed a high staging accuracy of 18F-FDG PET/CT in non-
small-cell lung cancer [99], breast cancer [100–103],
esophageal cancer [104, 105], colorectal cancer [106],
lymphoma [107], melanoma [108], cervical cancer [109],
head and neck cancers [110], bone and soft tissue sarcomas
[111, 112], and myeloma [113].
A recent meta-analysis determined the accuracy of
18F-FDG PET/CT for detecting distant metastases or syn-
chronous second cancers in more than 4,300 patients. On
the basis of prospectively defined criteria, 41 published
studies including patients with primary (n = 21 studies) or
recurrent (n = 14 studies) cancers and patients with pri-
mary and recurrent cancers (n = 6) were included [114]. In
addition, the diagnostic performance of PET/CT was
compared with that of conventional imaging in more than
800 patients. Histopathology served as the gold standard in
all patients. On a per patient basis, the sensitivity and
specificity of PET/CT averaged 93 and 96 %, respectively,
which compared favorably with the sensitivity of conven-
tional imaging (52 %). Numerous studies have demon-
strated the ability of 18F-FDG PET and PET/CT to assess
tumor responses to treatment performed as early as after a
single cycle of chemotherapy [115], at the middle of che-
motherapy, or at the end of chemotherapy [116••, 117, 118].
18F-FDG PET/CT has also been investigated as a prog-
nostic marker for outcome predictions. For instance, in 260
patients with Hodgkin’s lymphoma, positive PET findings
after two cycles of chemotherapy were associated with a
2-year progression-free survival of 13 %, whereas 95 % of
patients with negative PET findings were progression free
after 2 years [119]. Other studies confirmed these reports
[120]. PET-based risk-adapted therapies have also been
shown to be feasible in Hodgkin’s lymphoma [121].
Similar results were reported for non-Hodgkin’s lym-
phoma [122] and in a variety of solid tumors [123],
including cervical cancer [124], soft tissue sarcoma [115,
125] non-small-cell lung cancer [126–128], esophageal
cancer [129], breast cancer [130], gastric cancer [131], and
other types of cancer (reviewed in [116••, 117]).
Moreover, predictive biomarkers, i.e., those that deter-
mine whether therapeutic targets are present, have been
Fig. 2 University of California,
Los Angeles PET/CT protocol
providing a multiphase
abdominal CT scan, a breath-
hold chest CT scan, and a
whole-body contrast CT scan
performed during shallow
breathing for fusion with the
PET images. IV intravenous, PO
per os
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developed. These include, among others, androgen receptor
imaging [75, 132] and estrogen receptor ligands [74].
In general, tumor responses to neoadjuvant chemo(radi-
ation) therapy correlated with the fraction of necrotic tissue
in excised tumors. As a limitation, microscopic residual
disease cannot be identified with PET [133].
These results have several implications. First, neoadju-
vant therapy follows a predefined treatment protocol and
response or nonresponse only becomes evident after sur-
gical removal of the tumors, when changes in therapy can
no longer be implemented. Thus, interim 18F-FDG PET
could determine treatment efficacy early after the start of
chemotherapy. Second, unnecessary toxicity of ineffective
chemotherapies can be avoided. Third, postsurgical
chemotherapies could be tailored on the basis of presur-
gical treatment responses as determined by PET.
18F-FDG PET has also been used successfully to assess
tumor responses to targeted, predominantly cytostatic
therapies, including imatinib [134, 135], gefitinib [136],
erlotinib [137] (Fig. 3), and the B-Raf inhibitor PLX4032
[138] (Fig. 4). The prompt reduction of 18F-FDG tumor
uptake in response to imatinib and gefitinib appears to be
explained by a translocation of membrane-bound glucose
transporters into the cytoplasm and thus their inactivation
[139]. Moreover, erlotinib increases tumor tissue oxygen-
ation and reduces the tumor uptake of PET hypoxia probes,
which may also account for reductions in tumor 18F-FDG
uptake in response to treatment [140].
Combining anatomical and functional tumor response
assessments may further improve treatment response
assessments. Standardized uptake values (SUV) or meta-
bolic rates in micromoles per gram per minute describe
metabolic activity per gram of tissue but not metabolic
rates within the entire tumor volume [141]. This limitation
can be overcome with PET/CT by deriving the total lesion
glycolysis (i.e., SUV 9 volume) [31]. These or similar
approaches improved tumor response assessments in breast
cancer [142] and non-small-cell lung cancer [143] but not
in soft tissue sarcoma patients undergoing neoadjuvant
therapy [144]. A recent review emphasizes the need for
prospective studies to define the value of this integrated
approach for tumor treatment response assessments [145].
Impact of PET on Patient Management
Diagnostic accuracy and the ability to assess tumor
responses to treatment are only two possible end points of
clinical imaging studies. Other end points include impact
on patient management and outcome. The National
Oncologic PET Registry, which that now includes more than
300,000 patients [146, 147], provided evidence for a highly
significant impact of 18F-FDG PET on patient management
across a wide variety of cancers. Patient management was
affected in more than 30 % of all patients regardless of the
study indication. However, the National Oncologic PET
Registry did not address the impact of management changes
on patient outcome. The challenges to establish such evi-
dence have been summarized recently [148–150].
Standardization
Any imaging approach must be accurate and reproducible,
should provide clinically meaningful diagnostic and prog-
nostic information, and should improve patient manage-
ment and outcome. As mentioned earlier, a high accuracy
of PET/CT for diagnosing, staging, and therapy monitoring
has been established. A recent meta-analysis confirmed the
good reproducibility of 18F-FDG tumor uptake measure-
ments [151].
However, PET/CT protocols are not well standardized,
which is a precondition to achieve widespread adoption and
acceptance of any diagnostic modality. CT-based RECIST is
based on tumor size measurements whereby changes in
tumor size are used to define complete response, partial
response, and stable or progressive disease in response to
therapy [83, 152]. Limitations of the approach have been
summarized by Weber [30] and include (1) considerable
interobserver variability in size measurements, (2) inaccu-
rate differentiation between viable and nonviable tumor
Fig. 3 A 54-year-old female patient with non-small-cell lung cancer
and extensive metastatic disease to the bones as seen on fused sagittal
images (a, arrows). Two weeks after treatment with the endothelial
growth factor receptor inhibitor erlotinib, the bone metastases
demonstrate near complete resolution of 18F-FDG uptake (b)
182 Curr Radiol Rep (2013) 1:177–190
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resulting in underestimations of responses; (3) overestima-
tion of responses if tumor regrowth occurs rapidly, (4)
inability to differentiate stable disease from beneficial
response to (predominantly cytostatic) therapy, and (5)
apparent stable disease that denotes slowly growing tumors
rather than a beneficial response to treatment. However,
although inherently inaccurate [30], RECIST provides sim-
ple guidelines for defining response or nonresponse to ther-
apy. It is this simplicity that has led to the widespread
adoption of RECIST in clinical practice.
Matters are more complicated for PET. Recent surveys
highlight a substantial variability in image acquisition,
reconstruction, and analysis, emphasizing the need for
standardization in community-based [91] and academic
[92] imaging centers.
Boellaard [153] has provided highly useful suggestions
for image acquisition, reconstruction, and analysis meth-
ods. Young et al. [154] and Wahl et al. [118] have sug-
gested PET-based treatment response criteria. Response
criteria in lymphoma therapy have been adopted by many
centers [155, 156]. However, no international consensus
has been reached, a critically important shortcoming that
needs to be addressed urgently.
Demonstrating a beneficial impact of 18F-FDG on
patient outcome requires large trials with well-defined
clinical end points. Over the last few years several such
studies have been published. The PETAL trial was per-
formed in lymphoma patients who had positive findings on
pretreatment 18F-FDG scans [157]. Patients were initially
treated with two cycles of CHOP followed by an interim
PET scan. Treatment was continued in patients with neg-
ative PET findings, whereas those with positive PET
findings were randomized to receive six cycles of R-CHOP
versus an alternative therapy. Preliminary outcome data
after 6 months revealed that relapses occurred almost six
times more frequently in patients with positive findings on
interim PET scans than in those with negative findings on
interim PET scans (17 vs 3 %; p = 0.036).
The Municon trial was a nonrandomized study in
esophageal cancer patients that used 18F-FDG PET findings
2 weeks after the start of treatment to either proceed with
(in metabolic responders) or discontinue (in nonrespond-
ers) neoadjuvant therapy [158]. Nonresponding patients
underwent surgery. The improved survival of metabolic
responders underscored the feasibility and value of PET-
guided treatment decisions. As another example, lung
cancer patients who were randomized to presurgical
workup with PET/CT had a significantly lower number of
futile surgical procedures than those who underwent con-
ventional staging [99]. Finally, colorectal cancer patients
were randomized to either conventional follow-up or
18F-FDG PET follow-up [159]. Tumor recurrence was
detected significantly earlier in the PET group, and these
recurrences were more frequently cured by surgery.
Thus, PET-based risk-adapted therapy approaches are
feasible and can affect patient outcome beneficially.
The Cost (Effectiveness) of PET/CT
Diagnostic tests in cancer have to meet high cost-effec-
tiveness standards. The lack of agreement about basic
principles for generating such evidence has recently been
reviewed critically [150, 160].
High-end PET/CT systems range in price from $2.5
million to $3.0 million and operational costs including
Fig. 4 A 26-year-old female patient with metastatic melanoma with
PET body maximum intensity projection images at the baseline
(a) and after 8 weeks of treatment with a B-Raf inhibitor (b),
demonstrating complete resolution of abnormal 18F-FDG uptake.
Selected fused axial slices of a pretreatment and posttreatment hepatic
lesion (c, e) and right chest wall lesion (d, f)
Curr Radiol Rep (2013) 1:177–190 183
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service contracts are substantial. In the USA, 18F-FDG
PET/CT scans are currently reimbursed by Medicare at
$1,150 per scan This is comparable to the reimbursement
level of whole-body CT scans. Reimbursement for PET has
significantly decreased (by more than 40 %) over the last
10 years. Cancer imaging expenditure accounts for
approximately 4.6 % of overall Medicare cancer care costs
[161]. Approximately one fifth of this, or around 1 % of
Medicare expenditure, was incurred from PET/CT [162].
Although they are increasing at a lower rate, much more
significant costs arise from inpatient and outpatient care,
cancer drugs, physician services, and hospice care [162].
Moreover, individual procedural costs do not reflect the
cost-effectiveness of diagnostic tests. Several studies have
suggested that PET/CT is cost-effective across a variety of
cancers by improving patient management, which in turn
reduces downstream costs incurred because of incorrect
management decisions [99, 163–166].
Future Perspectives
Despite the emergence of PET/MRI [167–169] the role of
18F-PET/CT in initial and subsequent patient management
decisions will expand over the next decade. PET/MRI is
likely to find a role in addressing some specific clinical
questions. However, its high cost and operational complexity
suggests that its routine clinical use will remain limited.
Even currently, the use of MRI in cancer is significantly less
than that of CT. For instance, in patients diagnosed with
breast, colorectal, lung, and prostate cancer and lymphoma
in 2006, CT was used 3.5, 12, 5.5, 4, and 6.3 times more
frequently than MRI in the first 2 years after diagnosis [161].
These data are informative as they provide a realistic outlook
for the potential use of or market for PET/MRI in cancer.
Concerns about radiation exposure through medical
imaging have been raised [170]. Fully diagnostic PET/CT
studies may expose patients to radiation doses as high as
25 mSv. However, Brenner and Hall [170] have correctly
pointed to the greatly reduced relevance of this perceived
risk for patients with limited life expectancy [171]. Fur-
thermore, a recent analysis concluded that ‘‘risks of med-
ical imaging at effective doses below 50 mSv for single
procedures or 100 mSv for multiple procedures over short
time periods are too low to be detectable and may be
nonexistent’’ and that ‘‘predictions of hypothetical cancer
incidence and deaths in patient populations exposed to such
low doses are highly speculative and should be discour-
aged’’ because they ‘‘are harmful … and may cause some
patients and parents to refuse medical imaging procedures’’
[172].
PET/CT applications in oncology will be refined
by standardizing image acquisition, reconstruction, and
analysis as well by arriving at internationally accepted
treatment response criteria. Highly targeted imaging probes
to determine whether therapeutic targets are expressed and
active will emerge that will permit treatment stratification
and thus individualized therapy approaches. Generator-
based production of 68Ga permits the labeling of peptides
for peptide receptor imaging without the requirement of an
on-site cyclotron. This has expanded the use of PET to
include neuroendocrine tumors (68Ga DOTATATE, 68Ga
DOTATOC) [173, 174] and for depicting neoangiogenesis
using labeled RGD peptides [175]. Moreover, the labeling
of bombesin receptor agonists and antagonists shows
promise for imaging prostate cancer [176].
Other promising PET approaches include probes that
target cell surface antigens, intracellular proteins, and
hypoxia. PET reporter gene imaging will be used for
trafficking of cell-based therapies. Finally, drug develop-
ment will be facilitated by PET-based pharmacokinetic and
pharmacodynamic studies [177]. At the same time, func-
tional parameters such as tumor perfusion and texture will
be derived from dynamic CT images that will provide
indices of tumor vascularization and angiogenesis.
In summary, CT in PET/CT provides the anatomical
framework within which the biology of cancer can be
visualized by PET. This powerful combination will be used
to further refine diagnostic, prognostic, intermediate end
point, and predictive biomarkers in cancer patients. The
role of PET/MRI awaits definition. We believe that in
addition to the great potential in brain imaging, the
advantage of reduced radiation exposure could lead to
wider use in the pediatric population. Finally, cancer
patients who undergo MRI studies for cancer assessments
might very well benefit from the addition of PET in a single
session.
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